Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Prepaid Assets: 2019-2025

Historic Prepaid Assets for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $22.6 million.

  • Kymera Therapeutics' Prepaid Assets rose 29.77% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.6 million, marking a year-over-year increase of 29.77%. This contributed to the annual value of $20.6 million for FY2024, which is 76.26% up from last year.
  • As of Q3 2025, Kymera Therapeutics' Prepaid Assets stood at $22.6 million, which was down 1.16% from $22.9 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Prepaid Assets registered a high of $22.9 million during Q2 2025, and its lowest value of $4.8 million during Q2 2021.
  • In the last 3 years, Kymera Therapeutics' Prepaid Assets had a median value of $14.7 million in 2024 and averaged $16.4 million.
  • Data for Kymera Therapeutics' Prepaid Assets shows a peak YoY skyrocketed of 95.93% (in 2021) over the last 5 years.
  • Over the past 5 years, Kymera Therapeutics' Prepaid Assets (Quarterly) stood at $8.7 million in 2021, then increased by 11.39% to $9.7 million in 2022, then rose by 20.19% to $11.7 million in 2023, then spiked by 76.26% to $20.6 million in 2024, then climbed by 29.77% to $22.6 million in 2025.
  • Its Prepaid Assets was $22.6 million in Q3 2025, compared to $22.9 million in Q2 2025 and $17.8 million in Q1 2025.